ENTA News and Press, Enanta Pharmaceuticals Inc. From 08/16/21

- Initial Data Expected in the First Half of 2022 - Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it has dosed the first su...

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2021 Earnings Conference Call August 5, 2021, 4:30 PM ET Company Participants Jennifer Viera - Investor Relations Dr. Jay Luly - President and CEO Paul Mellett - Chief Financial Officer Nathalie Adda - Chief Medical Officer Conference Call Participants B...

Image source: The Motley Fool. Enanta Pharmaceuticals, inc (NASDAQ: ENTA) Q3 2021 Earnings Call Aug 5, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Enanta Pharmaceuticals, inc (ENTA) Q3 2021 Earnings Call Transcr...

Enanta Pharma (NASDAQ:ENTA): Q3 GAAP EPS of -$1.19 beats by $0.16. Revenue of $21.6M (+15.8% Y/Y) misses by $0.24M. Press Release For further details see: Enanta Pharma EPS beats by $0.16, misses on revenue

Nominates EDP-235, an Oral Protease Inhibitor Specifically Designed to Treat COVID-19, with a Phase 1 Study Planned for Early 2022 On Track to Dose First Subject in a Phase 1 Study of EDP-721, an Oral, Hepatitis B Virus (HBV) RNA Destabilizer Recently Reported Positi...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the nomination of EDP-235, its lead oral protease inhibitor specifically designed for the treatment of C...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2021 after the...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Nathalie Adda, M.D., Senior Vice President and Chief Medical Officer, will retire from Enanta in Fe...

The following slide deck was published by Enanta Pharmaceuticals, Inc. in conjunction with this event. For further details see: Enanta Pharma (ENTA) Investor Presentation - Slideshow

Enanta Pharmaceuticals (ENTA) announces new preclinical data for EDP-721, an oral hepatitis B virus ((HBV)) RNA destabilizer being developed for use in an all-oral combination regimen for HBV.The data demonstrate potent, selective and pangenotypic inhibition of HBV surface antigen (HBsAg), wi...